Bioinvent

BioInvent is a biopharmaceutical company that specializes in the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer treatment. The company's primary focus is the design of new therapeutic antibodies that can harness the body's own immune system to fight cancer.

History[edit | edit source]

BioInvent was founded in Lund, Sweden in 1997. The company has since grown to become a leading player in the field of oncology, with a strong focus on the development of innovative immunotherapy treatments.

Research and Development[edit | edit source]

BioInvent's research and development activities are primarily focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer treatment. The company's proprietary n-CoDeR library and F.I.R.S.T platform are used to identify and develop these antibodies.

The n-CoDeR library is a vast collection of fully human antibodies, while the F.I.R.S.T platform is a unique screening tool that allows for the simultaneous identification of antibodies that bind to tumor cells and immune effector cells.

Products[edit | edit source]

BioInvent's lead product candidate is BI-1206, a monoclonal antibody that is currently in clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company is also developing several other antibodies for the treatment of various types of cancer.

Partnerships[edit | edit source]

BioInvent has established several strategic partnerships with leading pharmaceutical and biotechnology companies. These partnerships have enabled the company to accelerate the development of its product candidates and expand its pipeline.